Clotrimazole/Betamethasone — $0 with Membership

About Clotrimazole/Betamethasone

Clotrimazole betamethasone is a topical medication used to treat a variety of fungal skin infections that are accompanied by inflammation, redness, or itching. This includes conditions like athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis). The clotrimazole component targets the fungal infection directly, while betamethasone, a corticosteroid, reduces the associated inflammation, redness, and itching, providing much-needed relief. It's not typically used for diaper rash, yeast infections in the vagina, or nail infections unless specifically directed by a healthcare professional. Always consult your doctor for a proper diagnosis and treatment plan.

How Clotrimazole Betamethasone Works

This medication combines two active ingredients, each with a distinct role. Clotrimazole is an antifungal agent that works by inhibiting the

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Clotrimazole/Betamethasone is approved for (FDA label)

Clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum in patients 17 years and older. Clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) contains a combination of clotrimazole, an azole antifungal, and betamethasone dipropionate, a corticosteroid, and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum in patients 17 years and older. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: July 28, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Clotrimazole/Betamethasone (FDA label)

Cream, 1%/0.05%. Each gram of clotrimazole and betamethasone dipropionate cream USP, 1%/0.05% (base) contains 10 mg of clotrimazole, USP and 0.64 mg of betamethasone dipropionate, USP (equivalent to 0.5 mg of betamethasone) in a white to off-white cream base. • Cream, 1%/0.05%. ( 3 ) • Each gram of clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) contains 10 mg of clotrimazole, and 0.64 mg of betamethasone dipropionate, (equivalent to 0.5 mg of betamethasone) in white to off-white cream base. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 55db730a-df6d-4950-9c26-91b06bdcef36. SPL document ID: 04a61040-37c4-4229-a1f9-8bd34c720e14. Label effective date: July 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Clotrimazole/Betamethasone (FDA label)

Most common adverse reactions reported for clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) were paraesthesia in 1.9% of patients and rash, edema, and secondary infections each in less than 1% of patients. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Fougera Pharmaceuticals Inc. at 1-800-645-9833 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials common adverse reaction reported for clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) was paresthesia in 1.9% of patients.

Source: FDA prescribing information (DailyMed). Set ID: 55db730a-df6d-4950-9c26-91b06bdcef36. SPL document ID: 04a61040-37c4-4229-a1f9-8bd34c720e14. Label effective date: July 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Clotrimazole/Betamethasone (FDA label)

None. • None. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 55db730a-df6d-4950-9c26-91b06bdcef36. SPL document ID: 04a61040-37c4-4229-a1f9-8bd34c720e14. Label effective date: July 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Clotrimazole/Betamethasone (FDA label)

• Clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) can cause reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency during and after withdrawal of the treatment. Risk factor(s) are: use of high-potency topical corticosteroid, use over a large surface area or to areas under occlusion, prolonged use, altered skin barrier, liver failure, and young age. Modify use should HPA axis suppression develop. ( 5.1 , 8.4 ) • Pediatric patients may be more susceptible to systemic toxicity. ( 5.1 , 8.4 ) • The use of clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) in the treatment of diaper dermatitis is not recommended. ( 5.2 ) • Topical corticosteroid products may increase the risk of cataracts and glaucoma.

Source: FDA prescribing information (DailyMed). Set ID: 55db730a-df6d-4950-9c26-91b06bdcef36. SPL document ID: 04a61040-37c4-4229-a1f9-8bd34c720e14. Label effective date: July 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.